A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon α and Ribavirin
| Autor: | Giuseppe Stefano Calvagno, B. Mauceri, Gianluca Mastrosimone, Antonino Judica, Agostino Rizzotto, Antonino Di Pino, Luca Ignaccolo, Sergio Neri, Antonio Petralia, Filippo Palermo, Giuseppe Vadalà, Daniela Maiorca, Gaetano Bertino, Giuseppe Abate, M. Misseri, P M Boemi, Crisafulli Giancarlo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Alpha interferon Interferon alpha-2 Chronic hepatitis C Antiviral Agents Severity of Illness Index Group B Polyethylene Glycols chemistry.chemical_compound symbols.namesake Drug Therapy Ribavirin medicine Humans Prospective Studies Chronic Adverse effect Psychiatry Severe psychiatric disorders Depression (differential diagnoses) Fisher's exact test business.industry Depression Gastroenterology Interferon-alpha Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins Psychotherapy Mood chemistry Combination symbols Interferon Drug Therapy Combination Female Drug Monitoring business |
| Popis: | GOALS To evaluate the effectiveness of psychiatric counseling in reducing the rate of development of psychiatric side effects of antiviral therapy with interferon-α and ribavirin among study participants compared with standard clinical monitoring alone. BACKGROUND Interferon-α is used to treat chronic hepatitis C. Interferons may induce adverse events that usually, but not always, reverse within a few days after the end of therapy. STUDY Two hundred eleven patients with chronic hepatitis C, genotype 1b were treated with peginterferon and ribavirin for 48 weeks in a prospective trial. Two groups were randomly created. Group A was interviewed by a team of gastroenterologists, psychiatrists, and psychologists and treated with psychotherapy once a month. Group B was monitored once a month according to a conventional protocol that did not include psychotherapy. SVR (sustained viral response), severe psychiatric symptom onset, and mood progression were assessed (P calculated using Fisher exact test, Friedman test, Dunn posttest, and Mann-Whitney U-test). RESULTS At baseline, there was no difference in depressive symptoms or liver histologic score between the 2 groups. The onset rate of severe psychiatric manifestations was 4.7% (Group A) and 16.1% (Group B) between the 24th and 36th weeks (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|